BRAND_ANALYSIS#ASTRAZENECAHEALTH & PHARMA#18 OF 26 IN HEALTH & PHARMAALIGNED
AstraZeneca
· Public · Updated 23 Aug 2026 07:27 UTC
#828 of 1208 overall by tension · #18 of 26 in Health & Pharma
11Aligned
The Balanced
Analysis
AstraZeneca's -0.40 sentiment is the COVID hangover: business (73) and cultural relevance (62) sustained by pharma necessity, but reputational damage from vaccine-rollout failures calcifying into skepticism. The gap widens as trust erodes.
IN THE NEWS (100 articles this week)
Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer - AstraZeneca
AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review - WSJ
AstraZeneca suffers another setback as it halts volrustomig lung cancer trial - Reuters